Monday, March 14, 2022 10:22:37 AM
https://www.businesswire.com/news/home/20220314005424/en/IPA-Selected-to-Work-with-Elektrofi-on-COVID-19-Therapeutic-Delivery-and-Future-Pandemic-Preparation-under-SBIR-Contract-from-Defense-Health-Agency-within-US-Department-of-Defense
BOSTON--(BUSINESS WIRE)--Elektrofi (ELEKTROFI, INC) & IPA (IMMUNOPRECISE ANTIBODIES LTD.) (NASDAQ: IPA) (TSXV: IPA) today announced they are entering into a collaboration to explore a high-concentration formulation of IPA’s COVID-19 antibody cocktail, PolyTope® TATX-03. This collaboration aims to generate an IND-enabling data package for the FDA for an alternatively formulated version of TATX-03, named TATX-03E, that could be easily self-administered in a non-healthcare setting. By joining forces, the parties anticipate formulating TATX-03E for stable and rapid distribution to the consumer, a drug product ideally suited to serve unmet needs for rapid deployment, field use, and higher frequency dosing for immunocompromised individuals requiring on-going access to therapies and prophylaxis.
The collaboration between Elektrofi and IPA will be supported by Elektrofi’s contract with the DHA Small Business Innovation Research (SBIR) Program within the Department of Defense (DoD). The companies will begin by conducting formulation feasibility studies followed by IND-enabling, non-clinical studies to establish safety and efficacy with the novel formulation.
“We are impressed by the neutralizing activity demonstrated by ImmunoPrecise’s antibody cocktail against current variants of concern, including Omicron. Nearly all other programs we have looked into partnering with do not demonstrate the ability to neutralize so many variants,” said Daniel Dadon, Director of Scientific Strategy at Elektrofi. “We look forward to working with IPA to develop a product that could potentially improve access to this class of life saving medicines and reduce the burden on healthcare systems.”
“Antibodies have been an essential asset for COVID-19 patients since their introduction earlier in the pandemic,” said Dr. Jennifer Bath, CEO and President of IPA. “We are excited to be working with Elektrofi and applying their formulation technology to these critical therapies, as self-administration could significantly alleviate the burden associated with COVID-19 and future pandemics, as well as other diseases.”
Recent IPA News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/23/2024 06:40:14 PM
- ImmunoPrecise Antibodies (IPA) publie ses résultats financiers et les faits saillants de ses activités du premier trimestre de l’exercice 2025 • Business Wire • 09/17/2024 02:13:00 AM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 09/16/2024 08:01:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 01:04:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 01:03:19 PM
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 • Business Wire • 09/16/2024 01:00:00 PM
- U.S. Markets Await Fed Decision and Empire State Report Amid Global Economic Shifts; Oil Prices Rise Slightly • IH Market News • 09/16/2024 10:04:55 AM
- IPA publiera le 16 septembre 2024 ses résultats financiers et les récents faits saillants de ses activités du premier trimestre de l’exercice 2024 • Business Wire • 09/09/2024 09:44:00 PM
- IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 • Business Wire • 09/09/2024 01:11:00 PM
- L'IPA participera à la 26e conférence annuelle mondiale de l'investissement organisée par H.C. Wainwright à New York • Business Wire • 08/26/2024 04:12:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/26/2024 01:41:08 PM
- ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York • Business Wire • 08/26/2024 01:00:00 PM
- ImmunoPrecise Antibodies reçoit un avis de la part du Nasdaq concernant les exigences minimales en matière d'offre • Business Wire • 08/24/2024 07:35:00 AM
- ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements • Business Wire • 08/24/2024 12:00:00 AM
- ImmunoPrecise Antibodies conçoit des anticorps in silico pour des protéines tumorales élusives en utilisant sa technologie LENSai brevetée • Business Wire • 08/19/2024 06:04:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 01:21:46 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/19/2024 04:15:03 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/06/2024 09:16:28 PM
- ImmunoPrecise Antibodies (IPA) publie ses résultats financiers et ses mises à jour commerciales pour le quatrième trimestre et l'exercice 2024 • Business Wire • 07/30/2024 01:05:00 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/29/2024 12:38:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/29/2024 12:35:02 PM
- ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 • Business Wire • 07/29/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/24/2024 01:55:46 AM
- ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 • Business Wire • 07/23/2024 11:30:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM